Prestige Consmr Healthcare Inc Stock Price, News & Analysis

Prestige Consumer Healthcare (PBH) reported strong financial results for fiscal 2022, with Q4 revenue of $266.9 million (up 12.3%) and full-year revenue of $1,086.8 million (up 15.2%). Adjusted diluted EPS for the year was $4.06 (up 25.3%). The company generated $259.9 million in net cash from operations, with record free cash flow of $253.7 million. The board authorized a $50 million share repurchase program. For fiscal 2023, PBH forecasts revenues between $1,120 million to $1,130 million, expecting organic growth of 2% to 3%.

Prestige Consumer Healthcare Inc. (NYSE:PBH) will issue its fiscal 2022 fourth quarter and year-end earnings on May 5, 2022, after market close. A conference call is scheduled for May 6 at 8:30 a.m. ET to discuss the results and company performance. Interested participants can join via phone or through an online webcast available on the company's Investor Relations page. Telephonic replays are accessible for a week post-call. Prestige Consumer Healthcare markets a variety of health products across North America and other markets.

Prestige Consumer Healthcare (NYSE:PBH) reported a 14.9% revenue increase to $274.5 million in Q3 2022, with a 22.2% rise in diluted EPS to $0.99. Nine-month revenues reached $819.9 million, up 16.2%. The company raised its full-year outlook, projecting revenue between $1,075 and $1,080 million, and adjusted EPS of $4.00 to $4.04. Strong performance stemmed from key brands, with increased demand in COVID-affected categories. Free cash flow for the quarter was $64.1 million, aiding in debt reduction.

Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2022 third quarter earnings on February 3, 2022, prior to market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results. U.S. and Canadian participants can dial 844-233-9440 or 574-990-1016 internationally, using conference ID 4798187. An internet webcast will be available, with a replay accessible from the Investor Relations page. Prestige markets a variety of consumer healthcare products including Monistat, BC, and Dramamine across several international markets.

Prestige Consumer Healthcare reported record revenue of $276.2 million for Q2 2022, a 16.3% increase from the previous year and 10.5% organic growth. The diluted EPS rose to $0.89, while adjusted EPS hit $1.02, reflecting a 30.8% year-over-year growth. Net operating cash flow was $61.2 million with adjusted free cash flow at $61.9 million. The company raised its full-year revenue and EPS guidance, anticipating total revenue between $1,050 million and $1,060 million while projecting adjusted EPS between $3.93 and $3.98.

Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2022 second quarter earnings on November 4, 2021, before market opening. A conference call to discuss the results is scheduled for the same morning at 8:30 a.m. ET, with dial-in options available for U.S. and international participants. An archived replay will be accessible on the company's Investor Relations page. Prestige Consumer Healthcare markets a diverse range of health products across North America and internationally.

Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2022 revenue of $269.2 million, marking a 17.3% increase from the previous year. Diluted EPS rose 32.5% to $1.14. Operating cash flow reached $69.3 million, while free cash flow was $67.8 million. The company raised its full-year outlook, projecting revenue of $1.045 billion or more and adjusted EPS of $3.90 or more, driven by solid brand performance and the recent acquisition of TheraTears, anticipated to add $40 million in revenue and $0.07 in EPS.

Prestige Consumer Healthcare Inc. (NYSE:PBH) has finalized its acquisition of TheraTears and other consumer brands from Akorn Operating Company for $230 million in cash. The asset purchase is expected to enhance Prestige's eye care portfolio, bringing approximately $60 million in annual revenue and contributing $20 million in EBITDA. The transaction is valued at under 10x pro-forma EBITDA, providing anticipated tax benefits of ~$30 million. The acquisition was financed through available cash, an Asset Based Loan, and refinancing of its term loan maturing in 2028.

Prestige Consumer Healthcare (NYSE:PBH) announced a $230 million cash acquisition of a portfolio from Akorn Operating Company, including the TheraTears brand. This acquisition is projected to generate approximately $60 million in annual revenue and $20 million in EBITDA. The transaction, expected to close in fiscal Q2, offers tax benefits of about $30 million and is valued at less than 10x pro-forma EBITDA. The TheraTears brand, a leader in the dry eye segment, aligns with Prestige's growth strategy and operational model.